Skip to main content

For 20 years, CRC has supported CNS clinical development through changes in science, technology, and regulatory expectations. One lesson has remained remarkably consistent: quality is strongest when specialized expertise comes together around the scientific question a study needs to answer.

Today, that principle is more important than ever. Regulatory expectations increasingly emphasize alignment among the question a study is intended to answer, the data it collects, and the analysis used to interpret those data. For sponsors, this means statistical thinking has value well beyond the final analysis.

Biostatistics, statistical programming, assessment expertise, clinical operations, and data management can work together throughout a study to help strengthen study design, recognize meaningful patterns in accumulating data, and investigate potential quality issues while the study is underway.

Twenty years of being bold has taught CRC that expertise matters. How that expertise comes together can matter just as much.

Clinical development moves quickly, and previous experience matters. A protocol from an earlier trial in the same indication may provide an excellent starting point for a new study. But simply carrying a previous design forward may not fully address today’s scientific and regulatory expectations or the particular objectives of the new trial.

Consider what happens when a participant stops study treatment but remains willing to be followed, begins another medication, misses an important assessment, or ultimately discontinues from the study. How these situations will be handled may affect more than the final statistical analysis. They can influence the protocol, data collection, participant follow-up, operational planning, and ultimately how confidently study results can be interpreted.

The practical lesson from ICH E9(R1) does not require every member of a sponsor’s study team to become a statistician. It is simpler: define the clinical question clearly and ensure that study design, conduct, data collection, and analysis remain aligned with that question.

That is why statistical thinking adds the greatest value when it is integrated into the study rather than treated primarily as a downstream analytical function.

Jeffrey Finman, Ph.D.

“Our role goes beyond delivering statistical outputs. By bringing biostatistics, statistical programming, assessment, clinical, and operational expertise together throughout a study, we can turn accumulating data into information that helps sponsors protect study quality and make better-informed decisions.”

Jeffrey Finman, Ph.D., Chief of Biostatistics

This collaboration can be particularly valuable in CNS trials, where rating scales may contain multiple items and subscales and several assessments may measure related aspects of a participant’s condition.

An individual response may appear entirely reasonable when examined in isolation. Looking across items, subscales, visits, related assessments, or raters, however, may reveal patterns that warrant closer examination. The objective is not to expect perfect agreement among assessments. It is to recognize signals that may merit investigation and bring the appropriate expertise to understanding them.

This presents an important opportunity to combine statistical programming with specialized assessment expertise. Customized data reviews can look for unexpected scoring patterns, consistency among related items and assessments, rater-related patterns, and other indicators of assessment-data quality.

“There is no ‘good enough’ when it comes to clinical trial data and analysis. By combining statistical programming with CRC’s in-house assessments expertise, we can conduct customized, ongoing reviews of scoring patterns, consistency across related items and assessments, rater-related outputs, and other indicators of assessment-data quality while there is still time to act.”

Zach Bezold, Director of Statistical Programming

Statistical programming is sometimes viewed primarily through its required deliverables: analysis datasets, tables, listings, figures, and other outputs needed for analysis and reporting. Those responsibilities are essential, but they do not represent the full potential contribution of statistical programming.

Working alongside biostatisticians, assessment specialists, data managers, clinicians, and operational teams, statistical programmers can help transform accumulating data into useful information about study conduct and quality.

The distinction matters.

The differentiator is not simply completing statistical and programming activities early enough to keep subsequent deliverables off the study’s critical path. The greater opportunity is to embed statistical thinking, programming, and cross-functional review into the study’s quality strategy throughout its conduct.

This approach can help study teams distinguish an isolated unusual observation from a broader pattern, determine when specialized expertise is needed, and address questions while there is still an opportunity to improve study quality.

Technology and sophisticated data review are only part of the equation. Clinical research inevitably presents situations in which the data, protocol, operational realities, and scientific objectives do not align as neatly as anyone would prefer.

Those situations require judgment.

They also require openness between the CRO and sponsor about what the data show, what remains uncertain, and the rationale for decisions made along the way. That is where experience and partnership become particularly important.

For sponsors, that distinction can be consequential. Deliverables are necessary. Evidence that remains scientifically credible when important development and regulatory decisions need to be made is the larger objective.

“The responsibility is to do the right thing and work through discrepancies with sponsors, so the reasoning is clear. The objective is not merely to produce a deliverable. It is to produce evidence that can withstand critical decisions.”

Brenda Krogen, Project Manager of Biostatistics

When evaluating a CRO for a CNS trial, sponsors should look beyond whether the expected statistical and programming deliverables appear in the scope of work. More revealing questions include:

  • How will you help ensure that our study design, data collection, and analysis all address the clinical question we ultimately need to answer?
  • How do your biostatistics, statistical programming, assessment, clinical, and operational experts actually work together throughout our study, rather than simply handing work from one function to the next?
  • When the data reveal something unexpected, how will you bring the right experts together to understand what it means and help us decide what to do next?

The answers can reveal something a list of deliverables cannot: whether a CRO is structured simply to execute the work or to become a scientific partner in helping the sponsor generate evidence it can confidently act upon.

Twenty years of experience does not mean doing things the way they have always been done. It means knowing which principles endure while recognizing when advances in science, regulation, technology, and clinical research require a better approach.

The fundamentals remain familiar: ask the right clinical question, design a study capable of answering it, collect high-quality data, and produce evidence that can be interpreted with confidence.

What continues to evolve is how effectively our team brings specialized expertise together around those goals.

For CRC, 20 years of bold means connecting biostatistics, statistical programming, assessment science, clinical expertise, operations, and data management with sponsors throughout the study. It means looking beyond individual deliverables to consider how each decision contributes to the quality and interpretability of the evidence the trial ultimately produces.

Twenty years have taught our team that being bold is not about accepting the way a study has always been done. It is about asking whether there is a better way.

If you are planning your next CNS trial, bring our team into the conversation while there is still an opportunity to shape the study, not simply execute it. Let’s talk about the question your trial needs to answer, the challenges you anticipate, and how CRC’s integrated expertise can help you build stronger evidence from the start.

Learn More

Own the Questions.

Lead the Outcome.

Download CRC’s Deck of Questions and take control of your CRO selection process with clarity, confidence, and zero wasted motion.